AI in Genomics Market 2022-2028

Description

List of Tables

Title:Global AI in Genomics Market Size, Share & Trends Analysis Report, By Delivery Mode (On-Premise and Cloud-Based), By Functionality (Genome Sequencing and Gene Editing), By Application (Translational Precision Medicine, Clinical and Genomic Diagnosis, and Others), By End-User (Pharmaceutical and Biotechnology Companies, Research Centers, Academic Institutes and Government Organizations, and Others), Forecast 2022-2028.

The global AI in genomics market is expected to grow at a significant CAGR of 50.2% during the forecast period. The rising investment by pharmaceutical companies and rising investment in the R&D in the drug discovery and drug development practices are expected to fuel the growth of the global AI in genomics market. The introduction of AI technology in the genomics field is expected to enhance operations, improve quality, and control the cost of activities. Drug discovery is a costly and time-consuming method; therefore, the demand for AI is expected to rise significantly, as AI delivers a quicker and cost-effective discovery process, and provides better success rates in the forthcoming future in the genomics industry.

Moreover, the growing adoption of AI in precision medicine, and funding provided by the government for genomic research have significantly driven the growth of the global AI in the genomics market. For instance, in September 2021, the Swedish government allocated an additional $9.4 million to Genomic Medicine Sweden (GMS), issued new diagnostic tools into healthcare, and contributes to more personalized care and treatment for precision medicine. The diagnostic toolkits include broad gene panels and whole-genome sequencing for analyzing cancers and rare diseases. Further, the funding is also intended to contribute to the ongoing introduction of precision medicine into healthcare, strengthening Swedish research and promoting new research and innovation collaborations between industry, healthcare, and academia. Therefore, the rising investment in the precision medicine field and significant benefits of using AI in the genomics field are supporting boost the market growth during the forecast period.

The global AI in genomics market is segmented based on delivery mode, functionality, application, and end-user. Based on the delivery mode, the market is segmented into on-premise and cloud-based. Based on functionality, the market is segmented into genome sequencing and gene editing. The gene editing segment is expected to show significant growth in the coming year. The growth is majorly attributed Owing to the factors such as the increasing application of gene editing technologies in the pharmaceutical, biotechnological, and agriculture sectors and rising research collaborations for gene editing. For instance, in June 2022, Immatics N.V., and Editas Medicine Inc., entered into a research collaboration and licensing agreement to combine gamma-delta T cell adoptive cell therapies and gene editing to develop medicines for the treatment of cancers. By combining Editas Medicine's gene editing technology with Immatics' ACTallo allogeneic, off-the-shelf adoptive cell therapy platform based on gamma-delta T cells, gamma-delta T cells the company delivers transformative medicines for the treatment of cancer. Based on application, the market is segmented into, translational precision medicine, clinical and genomic diagnosis, and others. Based on end-user, the market is segmented into pharmaceutical and biotechnology companies, research centers, academic institutes and government organizations, and others.

Geographically, the market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. The European region is expected to hold a prominent share in the global AI in genomics market. The rising application of AI across various end-user verticals such as animal research and drug discovery is driving the market growth in the region. Moreover, the presence of several research organizations is fostering the growth of the market in the European region.

The major companies operating in the global AI in genomics include IBM Corp., Microsoft Corp., Google LLC, and NVIDIA Corp., among others. The market players are focusing on the adoption of various strategies including mergers and acquisitions, partnerships, mergers and acquisitions, new product launches, and collaborations, to stay competitive in the market. For instance, in January 2022, BenevolentAI and AstraZeneca announced the expansion of AI powdered drug discovery which include disease areas such as systematic lupus erythematosus (SLE), and heart failure (HF). Leveraging the Benevolent Platform and biomedical Knowledge Graph will offer the scientists and technologists of BenevolentAI and AstraZeneca an improved understanding of the underlying disease mechanisms and identify new targets.

Research Methodology

The market study of the global AI in genomics market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives as possible, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include:

Financial reports of companies involved in the market.

Whitepapers, research papers, and news blogs.

Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

Global AI in Genomics Market Research and Analysis by Delivery Mode
Global AI in Genomics Market Research and Analysis by Functionality
Global AI in Genomics Market Research and Analysis by Application
Global AI in Genomics Market Research and Analysis by End-User

The Report Covers:

Comprehensive research methodology of the global AI in genomics market.
This report also includes a detailed and extensive market overview with key analyst insights.
An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
Analysis of regional regulations and other government policies impacting the global AI in genomics market.
Insights about market determinants that are stimulating the global AI in genomics market.
Detailed and extensive market segments with the regional distribution of forecasted revenues.
Extensive profiles and recent developments of market players.

Product Code: OMR2026758

1. Report Summary

Current Industry Analysis and Growth Potential Outlook
Recovery Scenario Of Global AI in Genomics Market
1.1. Research Methods and Tools
1.2. Market Breakdown
- 1.2.1. By Segment
- 1.2.2. By Region

2. Market Overview and Insights

2.1. Scope of the Report
2.2. Analyst Insight and Current Market Trends
- 2.2.1. Key Findings
- 2.2.2. Recommendations
- 2.2.3. Conclusion

3. Competitive Landscape

3.1. Key Company Analysis
- 3.1.1. IBM Corp.
  - 3.1.1.1. Overview
  - 3.1.1.2. Financial Analysis
  - 3.1.1.3. SWOT Analysis
  - 3.1.1.4. Recent Developments
- 3.1.2. Microsoft Corp.
  - 3.1.2.1. Overview
  - 3.1.2.2. Financial Analysis
  - 3.1.2.3. SWOT Analysis
  - 3.1.2.4. Recent Developments
- 3.1.3. Google LLC
  - 3.1.3.1. Overview
  - 3.1.3.2. Financial Analysis
  - 3.1.3.3. SWOT Analysis
  - 3.1.3.4. Recent Developments
- 3.1.4. NVIDIA Corp.
  - 3.1.4.1. Overview
  - 3.1.4.2. Financial Analysis
  - 3.1.4.3. SWOT Analysis
  - 3.1.4.4. Recent Developments
3.2. Key Strategy Analysis

4. Market Segmentation

4.1. Global AI in Genomics Market by Delivery Mode
- 4.1.1. On-Premise
- 4.1.2. Cloud-Based
4.2. Global AI in Genomics Market by Functionality
- 4.2.1. Genome Sequencing
- 4.2.2. Gene Editing
4.3. Global AI in Genomics Market by Application
- 4.3.1. Translational Precision Medicine
- 4.3.2. Clinical and Genomic Diagnosis
- 4.3.3. Others
4.4. Global AI in Genomics Market by End-User
- 4.4.1. Pharmaceutical and Biotechnology Companies
- 4.4.2. Research Centers, Academic Institutes, and Government Organizations
- 4.4.3. Healthcare Providers

5. Regional Analysis

5.1. North America
- 5.1.1. United States
- 5.1.2. Canada
5.2. Europe
- 5.2.1. UK
- 5.2.2. Germany
- 5.2.3. Italy
- 5.2.4. Spain
- 5.2.5. France
- 5.2.6. Rest of Europe
5.3. Asia-Pacific
- 5.3.1. China
- 5.3.2. India
- 5.3.3. Japan
- 5.3.4. South Korea
- 5.3.5. Rest of Asia-Pacific
5.4. Rest of the World

6. Company Profiles

6.1. BenevolentAI
6.2. Data4Cure, Inc.
6.3. Deep Genomics
6.4. Diploid Inc.
6.5. DNAnexus, Inc.
6.6. Empiric Logic
6.7. Engine Biosciences Pte. Ltd.
6.8. Fabric Genomics Inc.
6.9. FDNA
6.10. Freenome Holdings Inc.
6.11. GNX Data Systems Inc.Genoox
6.12. Lifebit Biotech Ltd.
6.13. Seragon Pharmaceuticals
6.14. Sophia Genetics
6.15. Verge Genomics